Loss of nuclear p27kip1 and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma

Cancer Science

Volumn 101, Issue 9, 2010, Pages 2080-2086

  Sgambato, Alessandro ^a   Camerini, Andrea ^b   Genovese, Giannicola ^a   De Luca, Filomena ^c   Viacava, Paolo ^c   Migaldi, Mario ^e   Boninsegna, Alma ^a   Cecchi, Massimo ^d   Sepich, Carlo A ^d   Rossi, Giulio ^e   Arena, Vincenzo ^a   Cittadini, Achille ^a   Amoroso, Domenico ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c Pathology   (Italy)

^d Ospedale Unico Della Versilia   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DYSTROGLYCAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DYSTROGLYCAN;

ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING; CANCER STAGING; CELL NUCLEUS; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTIVE VALUE;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DYSTROGLYCANS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 77955948282     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01644.x     Document Type: Article

References (33)

1. Lohse C, Cheville J. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 2005, 25:433-64.
2. Sobin L, Wittekind C. TNM Classification of Malignant Tumors 2002, eds, 6th edn, New York, Wiley
3. Eble J, Sauter G, Epstein J, Sesterhenn Ie. WHO Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs 2004, 65-7. Lyon, IARC Press
4. Sgambato A, Camerini A, Amoroso D. Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer Biol Ther 2007, 6:1840-6.
5. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27Kip1 and its alterations in tumor cells: a review. J Cell Physiol 2000, 183:18-27.
6. Langner C, von Wasielewski R, Ratschek M, Rehak P, Zigeuner R. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Wirchows Arch 2004, 445:631-6.
7. Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002, 94:973-9.
8. Grollman AP, Moriya M. Mutagenesis by 8-oxoguanine: an enemy within. Trends Genet 1993, 9:246-9.
9. Yin B, Whyatt RM, Perera FP. Determination of 8-hydroxy-deoxyguanosine by immunoaffinity chromatography-monoclonal antibody-based ELISA. Free Radic Biol Med 1995, 18:1023-32.
10. Sgambato A, Zannoni G, Faraglia B. Decreased expressions of the CDK inhibitor p27 kip 1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecol Oncol 2004, 92:776-83.
11. Fuhrman S, Lasky L, Limas C. Prognostic significance of morfologic parameters in renal carcinoma. Am J Surg Pathol 1982, 6:655-63.
12. Sgambato A, Migaldi M, Faraglia B. Loss of p27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999, 13:3245-50.
13. Sgambato A, Migaldi M, Leocata P. Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 2000, 89:2247-57.
14. Zannoni G, Faraglia B, Tarquini E. Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions. Mod Pathol 2006, 19:504-13.
15. Sgambato A, De Paola B, Migaldi M. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 2007, 213:528-39.
16. Sgambato A, Ratto G, Faraglia B. Reduced expression and altered subcellular localization of the CDK inhibitor p27Kip1 in human colon cancer. Mol Carcinog 1999, 26:172-9.
17. Santella RM. Immunological methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiol Biomarkers Prev 1997, 216:166-71.
18. Yarborouh A, Zhang Y-J, Hsu T-M, Santella RM. Immunoperoxidase detection of 8-hydroxydeoxyguanosine in aflatoxin B1 treated rat liver and human oral mucosa cells. Cancer Res 1996, 56:683-8.
19. Sgambato A, Brancaccio A. The dystroglycan complex: from biology to cancer. J Cell Physiol 2005, 205:163-9.
20. Sgambato A, Migaldi M, Montanari M. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003, 162:849-60.
21. Vervoorts J, Luscher J. Post-translational regulation of the tumor suppressor p27KIP1. Cell Mol Life Sci 2008, 65:3255-64.
22. Chu I, Hengst L, Slingerland J. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8:253-67.
23. Kim J, Jonasch E, Alexander A. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009, 15:81-90.
24. Sicinski P, Zacharek S, Kim C. Duality of p27Kip1 function in tumorigenesis. Genes Dev 2007, 21:1703-6.
25. Besson A, Hwang H, Cicero S. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and amultiple tumor phenotype. Genes Dev 2007, 21:1731-46.
26. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A. Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol 2007, 39:381-7.
27. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A. Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma. Int Urol Nephrol 2009, 41:243-9.
28. Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol 1999, 11:602-7.
29. Winder SJ. The complexities of dystroglycan. Trends Biochem Sci 2001, 26:118-24.
30. Gui GPH, Puddefoot JR, Vinson GP, Wells CA, Carpenter R. Altered cell-matrix contact: a prerequisite for breast cancer metastasis? Br J Cancer 1997, 75:623-33.
31. Gago-Dominguez M, Esteban Castelao J. Lipid peroxidation and renal cell carcinoma: further supportive evidence and new mechanistic insights. Free Radic Biol Med 2006, 40:721-33.
32. Bertoia M, Albanes D, Mayne S, Männistö S, Virtamo J, Wright ME. No association between fruit, vegetables, antioxidant nutrients and risk of renal cell carcinoma. Int J Cancer 2010, 126:1504-12.
33. Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.